[go: up one dir, main page]

MX2019008116A - Proceso para la preparacion de compuestos de 5-amino-6h-tiazolo[4, 5-d]pirimidina-2,7-diona 3-sustituidos. - Google Patents

Proceso para la preparacion de compuestos de 5-amino-6h-tiazolo[4, 5-d]pirimidina-2,7-diona 3-sustituidos.

Info

Publication number
MX2019008116A
MX2019008116A MX2019008116A MX2019008116A MX2019008116A MX 2019008116 A MX2019008116 A MX 2019008116A MX 2019008116 A MX2019008116 A MX 2019008116A MX 2019008116 A MX2019008116 A MX 2019008116A MX 2019008116 A MX2019008116 A MX 2019008116A
Authority
MX
Mexico
Prior art keywords
diona
thiazolo
pyrimidine
substitute
amino
Prior art date
Application number
MX2019008116A
Other languages
English (en)
Other versions
MX384745B (es
Inventor
Yu Jianhua
Meier Roland
Xiong Jing
Ren Yan
Chen Junli
Wang Xuemei
Konrath Manuel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2019008116A publication Critical patent/MX2019008116A/es
Publication of MX384745B publication Critical patent/MX384745B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención se refiere a un proceso para sintetizar un compuesto de fórmula (I), (I),(ver formula) R1 es H o alquilo C1-6; R2 es H o hidroxi; o una sal o diastereómero farmacéuticamente aceptable, que es útil para la profilaxis y el tratamiento de una enfermedad viral en un paciente relacionada con infección por hepatitis B o una enfermedad causada por infección por hepatitis B.
MX2019008116A 2017-01-06 2018-01-04 Proceso para la preparación de compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidina-2,7-diona 3-sustituidos. MX384745B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017070437 2017-01-06
CN2017112149 2017-11-21
PCT/EP2018/050159 WO2018127525A1 (en) 2017-01-06 2018-01-04 PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED 5-AMINO-6H-THIAZOLO[4,5-d]PYRIMIDINE-2,7-DIONE COMPOUNDS

Publications (2)

Publication Number Publication Date
MX2019008116A true MX2019008116A (es) 2019-09-04
MX384745B MX384745B (es) 2025-03-14

Family

ID=60953862

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008116A MX384745B (es) 2017-01-06 2018-01-04 Proceso para la preparación de compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidina-2,7-diona 3-sustituidos.

Country Status (11)

Country Link
US (1) US11142534B2 (es)
EP (1) EP3568400B1 (es)
JP (2) JP7201598B2 (es)
KR (1) KR102602328B1 (es)
CN (1) CN110139868B (es)
AU (2) AU2018205994B2 (es)
CA (1) CA3048768A1 (es)
IL (1) IL267801B2 (es)
MX (1) MX384745B (es)
TW (1) TWI808068B (es)
WO (1) WO2018127525A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX390374B (es) * 2017-01-06 2025-03-11 Hoffmann La Roche Nuevas formas solidas de acetato de[(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-tiazolo[4,5-d]pirimidin-3-il)-4-hidroxi tetrahidrofuran-2-il]propilo]
US11142534B2 (en) * 2017-01-06 2021-10-12 Hoffmann-La Roche Inc. Process for the preparation of 3-substituted 5-amino-6H-thiazolo[4,5-d]pyrimidine-2,7-dione compounds
US12012421B2 (en) 2017-07-07 2024-06-18 Hoffmann-La Roche Inc. Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
US12012420B2 (en) 2017-11-21 2024-06-18 Hoffmann-La Roche, Inc. Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
WO2025032082A1 (en) 2023-08-08 2025-02-13 F. Hoffmann-La Roche Ag Process for the preparation of 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476659A (en) 1982-11-09 1995-12-19 The Scripps Research Institute Cancerous B cell treatment using substituted nucleoside derivatives
US5166141A (en) 1983-11-01 1992-11-24 Scripps Clinic And Research Foundation Immunostimulating 7-deaza-7-oxa- and 7-deaza-7-oxo-analogs of 8-substituted-guanine-9-(1'-beta-D-aldoglycosidyl) derivatives and methods of treating test animals
US5041426A (en) 1987-12-21 1991-08-20 Brigham Young University Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides
FR2668153B1 (fr) * 1990-10-22 1995-03-31 Pasteur Merieux Serums Vacc Nouveaux composes ribonucleosides, leur procede de preparation et les medicaments les contenant.
EP1072607A3 (en) 1996-10-16 2001-09-12 ICN Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses therof
HUP0001186A3 (en) 1996-10-16 2002-04-29 Icn Pharmaceuticals Inc Costa Purine l-nucleosides,analogs and pharmaceutical compositions thereof
WO2005016235A2 (en) 2003-04-14 2005-02-24 The Regents Of The University Of California Combined use of impdh inhibitors with toll-like receptor agonists
EA200600540A1 (ru) 2003-09-05 2006-08-25 Анадис Фармасьютикалз, Инк. Введение лигандов tlr7 и их пролекарств для лечения инфекции вируса гепатита с
BRPI0518861B8 (pt) 2004-12-17 2021-05-25 Anadys Pharmaceuticals Inc compostos, sais ou hidratos farmaceuticamente aceitos, composição farmacêutica e uso de quantidade terapeutica ou profilaticamente eficaz de composto ou de composição farmacêutica
AU2006318260B2 (en) 2005-11-21 2012-05-17 Anadys Pharmaceuticals, Inc. Process for the preparation of 5-amino-3H- thiazolo [4 , 5 -d] pyrimidin- 2 -one
AR061024A1 (es) 2006-05-22 2008-07-30 Novartis Ag Maleato de 5-amino-3- (2'3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d] pirimidin-2-ona.
EP2034834B1 (en) 2006-06-22 2011-01-26 Anadys Pharmaceuticals, Inc. Prodrugs of 5-amino-3-(3'-deoxy-beta-d-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione
EP2040712B1 (en) 2006-07-18 2011-03-02 Anadys Pharmaceuticals, Inc. Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
BRPI0717741A2 (pt) 2006-10-17 2014-04-08 Anadys Pharmaceuticals Inc Compostos e respectivos método de preparação, método de redução de composto de sulfonil substituído, composição farmacêutica método de tratamento ou prevenção de doença
US20110166092A1 (en) 2007-08-20 2011-07-07 Anadys Pharmaceuticals, Inc. Dosing methods for treating disease
PE20170679A1 (es) 2014-12-08 2017-05-22 Hoffmann La Roche Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales
CR20170424A (es) * 2015-03-16 2018-01-26 Hoffmann La Roche Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsula del vhb
EP3294746B1 (en) 2015-05-12 2021-10-06 F. Hoffmann-La Roche AG Substituted aminothiazolopyrimidinedione derivatives for the treatment and prophylaxis of virus infection
WO2017001307A1 (en) 2015-06-30 2017-01-05 F. Hoffmann-La Roche Ag Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection
US11142534B2 (en) * 2017-01-06 2021-10-12 Hoffmann-La Roche Inc. Process for the preparation of 3-substituted 5-amino-6H-thiazolo[4,5-d]pyrimidine-2,7-dione compounds

Also Published As

Publication number Publication date
IL267801A (en) 2019-09-26
KR20190099492A (ko) 2019-08-27
JP7201598B2 (ja) 2023-01-10
CN110139868B (zh) 2021-07-09
AU2018205994B2 (en) 2021-09-09
EP3568400C0 (en) 2025-11-19
IL267801B2 (en) 2023-07-01
TW201829419A (zh) 2018-08-16
JP2020504126A (ja) 2020-02-06
CA3048768A1 (en) 2018-07-12
EP3568400A1 (en) 2019-11-20
EP3568400B1 (en) 2025-11-19
MX384745B (es) 2025-03-14
WO2018127525A1 (en) 2018-07-12
KR102602328B1 (ko) 2023-11-16
US20200024287A1 (en) 2020-01-23
BR112019013884A2 (pt) 2020-03-03
JP2023011699A (ja) 2023-01-24
CN110139868A (zh) 2019-08-16
AU2021258083A1 (en) 2021-11-25
AU2018205994A1 (en) 2019-06-13
US11142534B2 (en) 2021-10-12
TWI808068B (zh) 2023-07-11
IL267801B1 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
AR103222A1 (es) Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina
MX2019008116A (es) Proceso para la preparacion de compuestos de 5-amino-6h-tiazolo[4, 5-d]pirimidina-2,7-diona 3-sustituidos.
CL2022001739A1 (es) Compuestos tricíclicos sustituidos
EA201992601A1 (ru) Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak
MX2018009944A (es) Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbon il-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a- tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico.
MX374296B (es) Compuestos de pirazina novedosos para el tratamiento de enfermedades infecciosas
EA201391158A8 (ru) Диаминиевые соли фенотиазина и их применение
ZA202007566B (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
PE20151722A1 (es) Derivados de pirimidona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral
AR099134A1 (es) Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina
MX2017011951A (es) Derivados sustituidos de indol 3 novedosos, composiciones farmaceuticas y metodos para uso.
MX379474B (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales
PE20151542A1 (es) Compuestos de tetrahidropirrolotiazina
CO6670589A2 (es) Compuestos para reducir la producción de beta-amiloide
MD20160105A2 (ro) 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide
CR20140301A (es) Derivados de betulina
EA201591328A1 (ru) Замещенные гетероциклом тетрациклические соединения и способы их применения для лечения вирусных заболеваний
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
CU20200053A7 (es) Compuesto de pirimidina como inhibidor de las janocinasas, composición, forma cristalina y proceso de preparación
BR112018011788A2 (pt) formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
WO2014151630A3 (en) Compounds and compositions for the treatment of parasitic diseases
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
BR112018003489A2 (pt) n-[2-(2-amino-6,6-dissubstituído-4,4a,5,6-tetra-hidropirano[3,4-d][1,3]tiazin-8a(8h)-il)-1,3-tiazol-4-il]amidas
MX2020004930A (es) Compuestos de biarilo sustituido novedosos como inhibidores de indolamina 2,3-dioxigenasa (ido).